Innovations in the Identification, Prevention and Management of Diabetes-Related Foot Complications

Dear Colleagues,

Diabetes-related foot complications, including ulcers, infections, and neuropathies, represent a significant health challenge worldwide, often leading to severe outcomes such as amputations and reduced quality of life. As the global prevalence of diabetes continues to rise, the need for innovative approaches to address these complications is becoming increasingly urgent. Recent advancements in identifying, preventing, and managing diabetes-related foot complications are transforming patient care, reducing risks, and improving outcomes.

One of the critical areas of innovation is the development of advanced diagnostic tools. Traditional methods of diagnosing foot complications, such as visual inspections and physical examinations, are supplemented by new technologies like thermal imaging, hyperspectral imaging, and artificial intelligence (AI)-based algorithms. These technologies can detect early signs of foot ulcers or infections that are not visible to the naked eye, allowing for more precise and timely interventions. AI-powered tools are also used to analyze patient data and predict the risk of developing foot complications, enabling personalized preventive strategies.

Prevention remains a cornerstone in managing diabetes-related foot complications, and innovative strategies are emerging to address this need. Wearable devices, such as intelligent socks and insoles with sensors, can monitor foot temperature, pressure, and gait patterns, providing real-time data to patients and healthcare providers. These devices can alert users to potential issues, such as areas of high pressure or abnormal temperature changes, which are early indicators of ulcers or infections. By catching these problems early, patients and clinicians can take preventive actions, such as adjusting footwear or increasing foot care routines, to avoid serious complications.

Management of existing foot complications has also seen significant innovations. Regenerative medicine, including the use of stem cell therapy and growth factors, is showing promise in promoting wound healing and tissue regeneration in diabetic foot ulcers. Additionally, advanced wound care technologies, such as negative pressure wound therapy and bioengineered skin substitutes, are improving healing rates and reducing the risk of infection. The development of new antibiotics and antimicrobial dressings that target resistant bacteria is also crucial in managing infections more effectively.

Moreover, remote monitoring and telemedicine have become essential tools in managing diabetes-related foot complications, particularly during the COVID-19 pandemic. Telemedicine platforms enable regular follow-ups and consultations with healthcare providers, allowing continuous monitoring and early intervention without frequent in-person visits. This approach is particularly beneficial for patients in remote or underserved areas, where access to specialized care may be limited.

In conclusion, innovations in the identification, prevention, and management of diabetes-related foot complications are revolutionizing care and improving outcomes for patients. As these technologies continue to evolve and integrate into clinical practice, they hold great potential to reduce the burden of diabetic foot complications and enhance the quality of life for millions of people living with diabetes worldwide.

Dr. Aikaterini Andreadi
Guest Editor

Manuscript Submission Information

Manuscripts should be submitted online at www.mdpi.com by registering and logging in to this website. Once you are registered, click here to go to the submission form. Manuscripts can be submitted until the deadline. All submissions that pass pre-check are peer-reviewed. Accepted papers will be published continuously in the journal (as soon as accepted) and will be listed together on the special issue website. Research articles, review articles as well as short communications are invited. For planned papers, a title and short abstract (about 100 words) can be sent to the Editorial Office for announcement on this website.

Submitted manuscripts should not have been published previously, nor be under consideration for publication elsewhere (except conference proceedings papers). All manuscripts are thoroughly refereed through a single-blind peer-review process. A guide for authors and other relevant information for submission of manuscripts is available on the Instructions for Authors page. Diabetology is an international peer-reviewed open access monthly journal published by MDPI.

Please visit the Instructions for Authors page before submitting a manuscript. The Article Processing Charge (APC) for publication in this open access journal is 1200 CHF (Swiss Francs). Submitted papers should be well formatted and use good English. Authors may use MDPI's English editing service prior to publication or during author revisions.

• diabetic foot
• type 1 and type 2 diabetes
• micro and macrovascular complication